New MGA Analysis of the Adalimumab Biosimilars Market in the United States
The Biosimilars Council released the following statement in response to the new MGA report authored by Alex Brill and Christy Robinson.
New Report from MGA Examines the One-Year Cost Savings Lost Due to Patent Thickets
MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.”
New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit
A new MGA white paper from CEO Alex Brill and Principal Christy Robinson shows a positive outlook for biosimilar coverage in the commercial medical benefit.
Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology
MGA releases an updated report, “Biosimilar Market Opportunities in Ophthalmology.”
New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology
MGA releases a new report, “Biosimilar Market Opportunities in Ophthalmology.”
Alex Brill to FTC: Claims That PBMs Raise Drug Prices are Unfounded
In response to the FTC’s request for information regarding the business practices of pharmacy benefit managers (PBMs) and their impact on pharmacies and consumers, MGA’s Alex Brill submitted a letter detailing his findings.
- A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax Reform
- New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade
- Congress on the Brink of Disrupting the PBM Market
- Raising the Salt Cap Would Increase Tax Complexity
- Economics of “Delinking” Are Still Not Good
- The Child Tax Credit: Tradeoffs and Preferences
- Oregon’s Measure 118: The Turnover Tax Is the Worst
- Dueling Child Tax Credit Proposals: Harris vs. Vance
- Trump Proposes Bringing Back the Deduction for Auto Loan Interest
- Overtime Income Tax Break: Not Illogical, Just Costly and Complicated
